APTO-253

• CAT Number: I005464
• CAS Number: 916151-99-0
• Molecular Formula: C22H14FN5
• Molecular Weight: 367.38
• Purity: ≥95%
• Target: p21
• Solubility: DMSO: ≥ 26 mg/mL
• Storage: Store at -20°C
• IUPAC Name: 2-(5-fluoro-2-methyl-1H-indol-3-yl)-1H-imidazo[4,5-f][1,10]phenanthroline
• InChI: InChI=1S/C22H14FN5/c1-11-17(15-10-12(23)6-7-16(15)26-11)22-27-20-13-4-2-8-24-18(13)19-14(21(20)28-22)5-3-9-25-19/h2-10,26H,1H3,(H,27,28)
• InChIKey: NIRXBXIPHUTNNI-UHFFFAOYSA-N
• SMILES: CC1=C(C2=C(N1)C=CC(=C2)F)C3=NC4=C5C=CC=NC5=C6C(=C4N3)C=CC=N6

APTO-253（Cat No.:I005464）, also known as LOR-253 or LT-253, is a compound that inhibits the expression of c-Myc and selectively induces CDKN1A (p21). It exerts its effects by promoting G0-G1 cell cycle arrest and triggering apoptosis in acute myeloid leukemia (AML) cells. Additionally, APTO-253 acts as an inducer of Krüppel-like factor 4 (KLF4). These mechanisms make APTO-253 a promising candidate for the treatment of AML, potentially offering a targeted approach to disrupt cancer cell growth and promote cell cycle control.

Reference

[1]. APTO-253
[2]. Sakata VM, et al. High rate of clinical recurrence in patients with Vogt-Koyanagi-Harada disease treated with early high-dose corticosteroids. Graefes Arch Clin Exp Ophthalmol. 2015 May;253(5):785-790.